Drugs / alanyl-GLN dipeptide
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT00248638 Comparator | Sep 2006 → Dec 2012 | critical illness polyneuropathy | Emory University | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | alanyl-GLN dipeptide | “the GLN group (n = 75) received PN containing alanyl-GLN dipeptide (0.5 g/kg/d), proportionally replacing AA in PN (GLN-PN).” PMID 26501700 ↗ Apr 2016 |
| Modality | Peptide | “the GLN group (n = 75) received PN containing alanyl-GLN dipeptide (0.5 g/kg/d), proportionally replacing AA in PN (GLN-PN).” PMID 26501700 ↗ Apr 2016 |